Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2025
Reporting Period: Event date of June 5, 2025
Business Context: The Company is an emerging growth company incorporated in Delaware, trading on The Nasdaq Stock Market LLC. This filing reports the entry into a material definitive agreement and the appointment of a new executive officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on executive compensation and appointment details.
Material Changes and Executive Appointment
Appointment: The Board of Directors appointed Josh Neman as Chief Clinical Officer, effective June 5, 2025.
Compensation Package:
- Base Salary: $165,000 per year.
- Equity Grant: 200,000 Restricted Stock Units (RSUs) under the 2023 Equity Incentive Plan.
- Vesting Schedule:
- One-third vests on December 30, 2025.
- One-third vests in 29 equal monthly installments thereafter.
- One-third is performance-based, contingent on specific metrics.
Executive Background: Mr. Neman, age 47, is an Associate Professor at the Keck School of Medicine of USC and co-founder/CEO of Synaptical Inc. and CNSMENDER Consulting LLC.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to financial operations are disclosed in this report, other than the standard disclosure that the employment terms are subject to the full agreements filed as exhibits.
Key Facts for Investor Verification
- Verify the full terms of the Employment Agreement and Restricted Stock Award Agreement in Exhibits 10.1 and 10.2.
- Confirm the specific performance metrics required for the vesting of the performance-based RSUs.
- Review the Company's 2023 Equity Incentive Plan to understand the total pool of available equity and dilution implications.
- Assess the impact of the new Chief Clinical Officer's academic and startup background on the Company's clinical development strategy.